- Home
- REVBW vs ASLE Comparison
REVBW vs ASLE Comparison
Compare REVBW & ASLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVBW
- ASLE
- Stock Information
- Founded
- REVBW N/A
- ASLE 2008
- Country
- REVBW United States
- ASLE United States
- Employees
- REVBW 9
- ASLE N/A
- Industry
- REVBW Biotechnology: Pharmaceutical Preparations
- ASLE Industrial Specialties
- Sector
- REVBW Health Care
- ASLE Consumer Discretionary
- Exchange
- REVBW Nasdaq
- ASLE Nasdaq
- Market Cap
- REVBW N/A
- ASLE N/A
- IPO Year
- REVBW 2020
- ASLE N/A
- Fundamental
- Price
- REVBW $0.02
- ASLE $6.78
- Analyst Decision
- REVBW
- ASLE Strong Buy
- Analyst Count
- REVBW 0
- ASLE 3
- Target Price
- REVBW N/A
- ASLE $9.00
- AVG Volume (30 Days)
- REVBW N/A
- ASLE 693.2K
- Earning Date
- REVBW N/A
- ASLE 05-07-2025
- Dividend Yield
- REVBW N/A
- ASLE N/A
- EPS Growth
- REVBW N/A
- ASLE N/A
- EPS
- REVBW N/A
- ASLE 0.11
- Revenue
- REVBW N/A
- ASLE $345,066,000.00
- Revenue This Year
- REVBW N/A
- ASLE $14.51
- Revenue Next Year
- REVBW N/A
- ASLE $18.41
- P/E Ratio
- REVBW N/A
- ASLE $60.82
- Revenue Growth
- REVBW N/A
- ASLE 3.16
- 52 Week Low
- REVBW N/A
- ASLE $4.53
- 52 Week High
- REVBW N/A
- ASLE $9.40
- Technical
- Relative Strength Index (RSI)
- REVBW N/A
- ASLE 39.29
- Support Level
- REVBW N/A
- ASLE $6.63
- Resistance Level
- REVBW N/A
- ASLE $7.59
- Average True Range (ATR)
- REVBW 0.00
- ASLE 0.37
- MACD
- REVBW 0.00
- ASLE -0.09
- Stochastic Oscillator
- REVBW 0.00
- ASLE 35.37
About REVBW Revelation Biosciences Inc. Warrant
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).